Olverembatinib: First Approval
Sign Up to like & getrecommendations! Published in 2022 at "Drugs"
DOI: 10.1007/s40265-022-01680-9
Abstract: Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal… read more here.
Keywords: olverembatinib first; bcr abl1; cml; first approval ... See more keywords